Quidelortho Revenue Growth Rates (QDEL), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Quidelortho Corp  (NASDAQ: QDEL)
 

QDEL's Revenue Growth by Quarter and Year

Quidelortho's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

QDEL Revenue (in millions $) FY 2026 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September -
2nd Quarter June 630.90
1st Quarter March 619.80
FY 1,250.70

QDELs Annual Revenue
Quidelortho's Revenue in the fiscal year 2025 $ 2,730.20 millions
Quidelortho's Revenue in the fiscal year 2024 $ 2,782.90 millions
Quidelortho's Revenue in the fiscal year 2023 $ 2,997.80 millions
Quidelortho's Revenue in the fiscal year 2022 $ 3,266.00 millions
Quidelortho's Revenue in the fiscal year 2021 $ 1,698.55 millions




QDEL Revenue second quarter 2026 Y/Y Growth Comment
Quidelortho Corp reported Revenue growth of 2.77% year on year in the second quarter 2026, to $ 630.90 millions, this is lower than Quidelortho Corp's recent average Revenue improvement of 37.45%.

Looking into second quarter 2026 results within In Vitro & In Vivo Diagnostic Substances industry 5 other companies have achieved higher Revenue growth. While Quidelortho Corp' s Revenue increase of 2.77% ranks overall at the positon no. 2450 in the second quarter 2026.


QDEL Revenue ( Y/Y Growth %) 2026
 2025 2024 2023
4th Quarter December - 2.23 % -4.69 % -14.3 %
3rd Quarter September - -3.74 % -2.27 % -5.08 %
2nd Quarter June 2.77 % -3.63 % -4.22 % 8.43 %
1st Quarter March -10.54 % -2.56 % -15.97 % -15.58 %
FY   - -1.89 % -7.17 % -

Financial Statements
Quidelortho's second quarter 2026 Revenue $ 630.90 millions QDEL's Income Statement
Quidelortho's second quarter 2025 Revenue $ 613.90 millions Quarterly QDEL's Income Statement


QDEL Revenue (Quarter on Quarter Growth %)

 2026
 2025 2024 2023
4th Quarter December - 3.39 % -2.65 % -0.19 %
3rd Quarter September - 14.01 % 14.14 % 11.86 %
2nd Quarter June 1.79 % -11.39 % -10.41 % -21.39 %
1st Quarter March -14.34 % -2.12 % -4.26 % -2.36 %
FY (Year on Year)   - -1.89 % -7.17 % -


Back to QDEL Growth rate Comparisons >> Back to QDEL Growth rate Comparisons >>


Revenue second quarter 2026 Y/Y Growth Company Ranking
Within: No.
In Vitro & In Vivo Diagnostic Substances Industry #6
Healthcare Sector #350
Overall #2450

Revenue Y/Y Growth Statistics
High Average Low
431.75 % 37.45 % -100 %
(Mar 31 2021)   (Jun 30 2014)
Revenue second quarter 2026 Y/Y Growth Company Ranking
Within: No.
In Vitro & In Vivo Diagnostic Substances Industry #6
Healthcare Sector #350
Overall #2450
Revenue Y/Y Growth Statistics
High Average Low
431.75 % 37.45 % -100 %
(Mar 31 2021)   (Jun 30 2014)

Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026

Quidelortho's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
188.62 % 11.58 % -100 %
(Sep 30 2021)  


QDEL's II. Quarter Q/Q Revenue Comment
Quidelortho Corp achieved in the II. Quarter 2026 below company average Revenue growth of 1.79% quarter on quarter, to $ 630.90 millions.

Although the II. Quarter 2026 Revenue Q/Q growth was lower than the regular , this has been yet encouraging story, as the II. Quarter surge, eclipses the -11.39% growth in the II. Quarter a year ago

Within In Vitro & In Vivo Diagnostic Substances industry 2 other companies have achieved higher Revenue quarter on quarter growth. While Quidelortho's Revenue growth quarter on quarter, overall rank is 1436.


Revenue Q/Q Growth Company Ranking
Within: No.
In Vitro & In Vivo Diagnostic Substances Industry #3
Healthcare Sector #197
Overall #1436
Revenue Q/Q Growth Company Ranking
Within: No.
In Vitro & In Vivo Diagnostic Substances Industry #3
Healthcare Sector #197
Overall #1436
Revenue Q/Q Growth Statistics
High Average Low
188.62 % 11.58 % -100 %
(Sep 30 2021)  


QDEL's II. Quarter Q/Q Revenue Comment
Quidelortho Corp achieved in the II. Quarter 2026 below company average Revenue growth of 1.79% quarter on quarter, to $ 630.90 millions.

II. Quarter 2026 Revenue Q/Q growth were paradoxical, although lower than the regular, yet it demonstrates absolute recovery measured to the -11.39% in the II. Quarter a year ago.

Within In Vitro & In Vivo Diagnostic Substances industry 2 other companies have achieved higher Revenue quarter on quarter growth. While Quidelortho's Revenue growth quarter on quarter, overall rank is 1436.


Quidelortho's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Jun 28 2026)		 12 Months Ending
(Mar 29 2026)		 12 Months Ending
(Dec 28 2025)		 12 Months Ending
(Sep 28 2025)		 12 Months Ending
(Jun 29 2025)
Cumulative Revenue 12 Months Ending $ 2,674.20 $ 2,657.20 $ 2,730.20 $ 2,714.40 $ 2,741.60
Y / Y Revenue Growth (TTM) -2.46 % -3.89 % -1.89 % -3.67 % -3.28 %
Year on Year Revenue Growth Overall Ranking # 2733 # 2705 # 1752 # 2544 # 0
Seqeuential Revenue Change (TTM) 0.64 % -2.67 % 0.58 % -0.99 % -0.84 %
Seq. Revenue Growth (TTM) Overall Ranking # 2534 # 2486 # 1581 # 2138 # 0


Cumulative Revenue growth Comment
Quidelortho showed decline, but improvement compare to trailing twelve month Revenue decrease in Mar 29 2026. If the fiscal year would end in Jun 28 2026, Quidelortho's annual Revenue decline would be -2.46% year on year to $2,674 millions.

In the Healthcare sector 389 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 2705 to 2733.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
In Vitro & In Vivo Diagnostic Substances Industry # 8
Healthcare Sector # 390
Overall # 2733

Revenue TTM Y/Y Growth Statistics
High Average Low
231.63 %
 32.85 %
-11.79 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 8
Sector # 366
S&P 500 # 2534
Cumulative Revenue growth Comment
Quidelortho showed decline, but improvement compare to trailing twelve month Revenue decrease in Mar 29 2026. If the fiscal year would end in Jun 28 2026, Quidelortho's annual Revenue fall would be -2.46% year on year to $2,674 millions.

In the Healthcare sector 389 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 2705 to 2733.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
In Vitro & In Vivo Diagnostic Substances Industry # 8
Healthcare Sector # 390
Overall # 2733

Revenue TTM Y/Y Growth Statistics
High Average Low
231.63 %
32.85 %
-11.79 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 8
Sector # 366
S&P 500 # 2534




Other Revenue Growth
In Vitro & In Vivo Diagnostic Substances Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
QDEL's Revenue Growth Ratio versus In Vitro & In Vivo Diagnostic Substances Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue fall for the quarter ending Jun 28 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending Jun 28 2026
Zimmer Biomet Holdings Inc 4.80%$ 4.799 millions
Mettler toledo International Inc 4.48%$ 4.485 millions
Phibro Animal Health Corporation4.40%$ 4.405 millions
Align Technology inc 4.35%$ 4.355 millions
Opko Health Inc 4.32%$ 4.319 millions
Dariohealth Corp 4.29%$ 4.291 millions
Orthofix Medical Inc 4.15%$ 4.147 millions
Pediatrix Medical Group Inc 4.04%$ 4.040 millions
Nrc Health3.98%$ 3.978 millions
Bioventus Inc 3.76%$ 3.757 millions
Heron Therapeutics Inc 3.64%$ 3.640 millions
Prime Medicine Inc 3.50%$ 3.498 millions
Inogen Inc 3.04%$ 3.042 millions
Pacific Health Care Organization Inc2.79%$ 2.786 millions
Quidelortho Corp2.77%$ 2.769 millions
C4 Therapeutics Inc 2.75%$ 2.754 millions
Surgery Partners Inc 2.75%$ 2.748 millions
Lantheus Holdings Inc 2.69%$ 2.690 millions
Healthcare Services Group Inc 2.69%$ 2.686 millions
Adma Biologics Inc 2.61%$ 2.613 millions
Pfizer Inc2.60%$ 2.600 millions
Infusystem Holdings Inc2.59%$ 2.586 millions
Outset Medical Inc 2.49%$ 2.488 millions
3m Company2.46%$ 2.459 millions
Strata Critical Medical Inc 2.41%$ 2.408 millions
Nature s Sunshine Products inc 2.35%$ 2.350 millions
Solventum Corporation2.22%$ 2.221 millions
Adc Therapeutics Sa2.17%$ 2.171 millions
Moderna Inc 2.11%$ 2.113 millions
Co diagnostics Inc 1.98%$ 1.977 millions


About Quidelortho Revenue Growth Rates (QDEL), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Quidel Corp (CIK 353569).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0000353569-22-000043
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Quidel Corp ’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.